Amgen Stock Soars on Tezepelumab Phase‑III Win, But Long‑Term Outlook Still Uncertain
Amgen stock surges on Tezepelumab Phase‑III success, but investors weigh future growth versus market volatility and regulatory risks.
3 minutes to read
AMGEN INC
Amgen Shares Slip 0.14% to $449.04 Amid Market Gains and Oncology Focus
Amgen shares dip 0.14% at $449.04, staying above its 200‑day MA while the biotech sector sees modest gains; investors eye upcoming oncology webcast.
2 minutes to read
Amgen Shares Surge 3.3% to $438 – Outperforming Biotech Peers & Outpacing 52‑Week High
Amgen shares rise 3.29% to $438.34, topping 52‑week highs and outperforming biotech peers. See why the rally matters for investors.
2 minutes to read
Amgen Slides 1.75%: Why Biotech Investors Should Watch Its Pipeline Closely
Amgen dips 1.75% amid biotech market wobble—investors weigh pipeline strength, regulatory risks, and peer valuations for next move.
4 minutes to read